Iterion Therapeutics
Iterion Therapeutics is a clinical-stage biopharmaceutical company dedicated to revolutionizing healthcare through novel drug discovery and innovation, focusing on developing therapeutics for cancer, notably their lead product tegavivint, which targets the Wnt/beta-catenin signaling pathway.
Industries
biotechnology
pharmaceutical
therapeutics
Nr. of Employees
small (1-50)
Iterion Therapeutics
7255 Helix Park Avenue, Houston, TX 77030
Patents
Products
Lead clinical-stage small-molecule TBL1 inhibitor (clinical candidate)
A first-in-class small-molecule inhibitor that binds TBL1 to displace nuclear beta-catenin, promoting its degradation and inhibiting downstream oncogenic transcription; developed for multiple cancer indications including hepatocellular carcinoma and desmoid tumors.
Lead clinical-stage small-molecule TBL1 inhibitor (clinical candidate)
A first-in-class small-molecule inhibitor that binds TBL1 to displace nuclear beta-catenin, promoting its degradation and inhibiting downstream oncogenic transcription; developed for multiple cancer indications including hepatocellular carcinoma and desmoid tumors.
Services
Partnerships with academic and clinical investigators to evaluate company therapeutic candidates in investigator-initiated studies.
Partnerships with academic and clinical investigators to evaluate company therapeutic candidates in investigator-initiated studies.
Expertise Areas
- Oncology drug development
- Targeted therapy for Wnt/beta-catenin pathway
- Small-molecule drug discovery
- Translational research and biomarker-driven development
Key Technologies
- Small-molecule inhibitor development
- Target-based disruption of protein–protein interactions
- In vitro cellular cancer models
- In vivo tumor models